← Back to Search

CAR T-cell Therapy

CAR T Cells for Lymphoma

Phase 1
Recruiting
Led By Matthew Frank, MD, PhD
Research Sponsored by Stanford University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 years
Awards & highlights
No Placebo-Only Group

Summary

This trial will test the safety and effectiveness of CD22CART treatment in adults with relapsed or refractory B Cell Lymphomas. They will follow participants to see how long they survive, how

Who is the study for?
This trial is for adults with certain types of B Cell Lymphomas that have come back or haven't responded to treatment. Participants must have tried at least two prior therapies, including one with an anti-CD20 monoclonal antibody and chemotherapy. They should not be eligible if they've had fewer than two previous lines of therapy or don't meet specific disease progression criteria.
What is being tested?
The trial tests CD22CART Infusion after lymphodepleting chemotherapy in patients with relapsed/refractory B Cell Lymphomas. It aims to assess the safety and effectiveness by tracking overall survival, progression-free survival, and duration of response post-treatment.
What are the potential side effects?
Potential side effects may include reactions related to the infusion process, immune system complications due to CAR T-cell activity against cancer cells, as well as general symptoms like fatigue, fever, or chills from the body's response to treatment.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Determine the manufacturing feasibility of CD22 CART by assessing the target dose level and release specifications in each disease cohort.
Determine the overall response rate (ORR) in adults with follicular lymphoma (FL) and mantle cell lymphoma (MCL)
Maximum tolerated dose (MTD)/recommended phase 2 dose (RP2D)
Secondary study objectives
Assess the response rate in adults with relapsed/refractory Hairy cell leukemia (HCL), Lymphoplasmacytic lymphoma (Waldenstrom macroglobulemia) (WM), Burkitt lymphoma (BL), and Marginal Zone lymphoma (MZL).
Evaluate Duration of Response (DOR)
Evaluate Overall Survival (OS)
+1 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

3Treatment groups
Experimental Treatment
Group I: Cohort 3: Other lymphomasExperimental Treatment1 Intervention
up to 30 participants with no more than 10 of any one type, including: Hairy cell leukemia, Lymphoplasmacytic lymphoma (Waldenstrom macroglobulinemia), Burkitt lymphoma, and Marginal zone lymphoma.
Group II: Cohort 2: Mantle cell lymphoma (MCL)Experimental Treatment1 Intervention
12-32 participants with MCL will be administered the RP2D of CD22CART.
Group III: Cohort 1: Follicular lymphoma (FL)Experimental Treatment1 Intervention
18-34 participants with FL will be administered the RP2D of CD22CART

Find a Location

Who is running the clinical trial?

Stanford UniversityLead Sponsor
2,467 Previous Clinical Trials
17,495,995 Total Patients Enrolled
1 Trials studying Burkitt Lymphoma
3 Patients Enrolled for Burkitt Lymphoma
The Leukemia and Lymphoma SocietyOTHER
85 Previous Clinical Trials
26,174 Total Patients Enrolled
Matthew Frank, MD, PhDPrincipal InvestigatorStanford University
1 Previous Clinical Trials
52 Total Patients Enrolled
~80 spots leftby Apr 2031
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top